SLS — Sellas Life Sciences Group Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $5.03
- 30-Day Move
- +156.6%
- Market Cap
- $952M
- Shares Outstanding
- 179,540,000
- P/B Ratio
- 7.73
- ROE
- -327.5%
Analyst consensus: Buy · 7 analysts
Sellas Life Sciences Group Inc
A read-only Alphactor snapshot forSellas Life Sciences Group Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$5.03
30-Day Move
+156.6%
Market Cap
$952M
Shares Outstanding
179,540,000
P/B Ratio
7.73
ROE
-327.5%
$5.03
+156.6%last 90 delayed daily bars
90D High
$6.14
90D Low
$1.84
Avg Volume
8,163,217
Gross margin is running at 93.1%, which gives a quick read on operating quality before you open the full model.
Net margin is -736.2%, useful for comparing SLS against peers in Biotechnology.
SLS is up 156.6% over the last 30 trading days shown on this page.
Latest operating income is $-28M, which helps anchor the headline ratios with an actual earnings figure.
Dark Pool Short %
71.1%
Latest Close
$5.03
30-Day Move
+156.6%
Market Cap
$952M
Shares Outstanding
179,540,000
P/B Ratio
7.73
ROE
-327.5%
ROA
-159.5%
Gross Margin
93.1%
Operating Margin
-730.7%
Net Margin
-736.2%
Debt / Equity
0
Current Ratio
1.72
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-28M
Net Income
$-27M
Gross Margin
9310.0%
Net Margin
-73621.0%
Current Ratio
1.72
Debt / Equity
0.00
Altman Z
71.35
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
1.06x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1M | $-32M | $-41M | $-28M |
| 2023-12-31 | $0 | $-38M | $-37M | $-37M |
| 2024-12-31 | $0 | $-32M | $-31M | $-35M |
| 2025-12-31 | $0 | $-28M | $-27M | $-28M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Buy Value
$185,406
Sell Value
$0
Buys
4
Sells
0
Buy Value
$185,406
Sell Value
$0
Buy/Sell Ratio
4.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-07 | Varian John | A | 50,000 | $0.00 |
| 2026-01-07 | CICIC DRAGAN | A | 300,000 | $0.00 |
| 2026-01-07 | Burns John Thomas | A | 300,000 | $0.00 |
| 2026-01-07 | Kalin Katherine Bach | A | 50,000 | $0.00 |
| 2026-01-07 | Wasman Jane | A | 50,000 | $0.00 |
| 2026-01-07 | SCHEINBERG DAVID A | A | 50,000 | $0.00 |
| 2026-01-07 | VAN NOSTRAND ROBERT L | A | 50,000 | $0.00 |
| 2025-12-03 | CICIC DRAGAN | J | 63,800 | $1.50 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4,907,430 | 0.03% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4,474,967 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 3,060,502 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,566,528 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1,203,198 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 1,032,612 | 0.01% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 746,357 | 0.00% | 2026-02-28 |
| VANGUARD WELLINGTON FUND-Vanguard U.S. Momentum Factor ETF | 509,816 | 0.00% | 2025-11-30 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Vanguard Group
Filed 2026-01-29
$32M
+23.8%
Geode Capital Management
Filed 2026-02-09
$12M
+35.9%
Citadel Advisors
Filed 2026-02-17
$7M
--
Marshall Wace
Filed 2026-02-13
$5M
--
Northern Trust
Filed 2026-02-17
$4M
+27.3%
Goldman Sachs
Filed 2026-02-10
$2M
+2036.8%
4.14
Consensus
Buy—
—
—
7
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.